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Abstract
Purpose Patients at high non-sudden cardiac death risk may
gain no significant benefit from implantable cardioverter-
defibrillator (ICD) therapy. A number of approaches have
been proposed to identify these patients, including single clin-
ical markers and more complex scoring systems. The aims of
this study were to use the proposed scoring systems to (1)
establish how many current ICD recipients may be too high
risk to derive significant benefit from ICD therapy and (2)
evaluate how well the scoring systems predict short-termmor-
tality in an unselected ICD cohort.
Methods We performed a single-centre retrospective observa-
tional study of all new ICD implants over 5 years (2009–2013).
We used four published scoring systems (Bilchick, Goldenberg,
Kramer and Parkash) and serum urea to identify new ICD re-
cipients whose short-term predictedmortality risk was high.We
evaluated how well the scoring systems predicted death.
Results Over 5 years, there were 406 new implants (79%
male, mean age 70 (60–76), 58% primary prevention).
During a follow-up of 936 ± 560 days, 96 patients died.
Using the scoring systems, the proportion of ICD recipients
predicted to be at high short-term mortality risk were 5.9%
(Bilchick), 34.7% (Goldenberg), 7.4% (Kramer), 21.4%
(Parkash) and 25% (urea, cut-off of >9.28 mM). All four risk
scores predicted mortality (P < 0.0001); however, none
outperformed urea for the prediction of 1- or 3-year mortality.
Conclusions Using published scoring systems, a significant
proportion of current ICD recipients are at high short-term
mortality risk. Although all four scoring systems predicted
mortality during follow-up, none significantly outperformed
serum urea.
Keywords Implantable cardioverter-defibrillator . Mortality .
Scoring system . Urea
1 Introduction
The implantable cardioverter-defibrillator (ICD) is a highly
effective therapy for the prevention of sudden cardiac death
(SCD) in high-risk patients [1]. However, many patients
whose risk of short-term mortality following device implanta-
tion is high may gain no significant benefit from an ICD,
irrespective of their SCD risk. Such patients, who have signif-
icant non-cardiac comorbidity or advanced heart failure, typ-
ically die of a non-cardiac cause or pump failure [2, 3]. These
patients are important as they are exposed to all of the risks of
ICD therapy, without the opportunity to gain significant mor-
tality benefit.
A number of complex scoring systems have been proposed
to identify these high-risk patients [4–7] (Table 1). However, it
is unclear which scoring system is most useful and whether
any add incremental value compared to a single risk marker
alone (serum urea).
The aims of this study were to use the proposed scor-
ing systems to (1) establish how many current ICD recip-
ients may be too high risk to derive significant benefit
from ICD therapy and (2) evaluate how well the proposed
scoring systems predict short-term mortality in an unselect-
ed cohort of ICD recipients.
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We conducted a single-centre retrospective analysis of consec-
utive patients undergoing first time ICD implantation at
King’s College Hospital (London, UK) between January
2009 and October 2013.
2.2 Derivation of risk scores
The presence or absence of specific clinical variables such as
atrial fibrillation (AF), diabetes, peripheral arterial disease
(PAD) and chronic obstructive pulmonary disease at the time
of ICD implant were determined by review of the clinical
records.
Assigned or measured variables such as age, New York
Heart Association (NYHA) heart failure functional class, cre-
atinine, urea, QRS duration and left ventricular ejection frac-
tion (LVEF) were taken at the time of ICD implant or the
closest available value.
AF was defined as a history of paroxysmal or permanent
AF on the electrocardiogram. PAD was defined as in the
Kramer study; a patient had an intervention on the carotid
arteries or lower extremities, thoracic or abdominal aorta or
had clinical claudication [6]. Chronic kidney disease was
defined as an estimated glomerular filtration rate of <60 mL/
min/1.73m2 using the modification of diet in renal disease
equation.
2.3 Statistical analysis
Continuous variables are presented as median (interquartile
range) and categorical variables are expressed as absolute
and relative frequency.
The Bilchick [4], Goldenberg [5], Kramer [6] and Parkash
[7] risk scores were calculated from patients’ clinical charac-
teristics according to the original publications. On the basis of
these risk scores, patients were further classified into risk cat-
egories as set out in the papers [4–7]. The Bilchick, Kramer
and Parkash models distinguished two risk categories for mor-
tality (low and high risk). In the Goldenberg model, patients
were stratified in three risk categories for mortality (low, in-
termediate and high risk). For the purposes of our study, we
combined the low and intermediate categories into one ‘low-
risk’ group. We used serum urea to categorize patients into
low and high risk, based on the value derived from the
Goldenberg study, an analysis of MADIT-2 (cut-off of
>9.28 mM) [5].
Cox proportional hazards regressionmodelling was used to
evaluate the independent contribution of each of the clinical
parameters within all scoring systems to the occurrence of
Table 1 Scoring systems to
identify patients at high risk of
early mortality after ICD
implantation
Clinical parameter Scoring system
Goldenberg Bilchick Kramer Parkash
Age >70 years ≥75 years ≥70 years >80 years
Points 1 62 1 1
Atrial fibrillation ✓ ✓ ✓
Points 1 27 1











NYHA functional class >II > II >II
Points 1 36 1
Peripheral arterial disease ✓
Points 1
QRS duration >120 ms
Points 1
COPD chronic obstructive pulmonary disease, LVEF left ventricular ejection fraction, NYHA New York Heart
Association
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mortality during follow-up. Each clinical parameter and risk
scoring system was first entered into a univariate model, and
those found to be significant at a level of P < 0.02 were then
entered into a stepwise forward multivariate model.
Risk model calibration was assessed by the Hosmer-
Lemeshow goodness-of-fit test, which determines how close
the predicted and observed incidence of events is over a range
of scores. In this test, a significant result indicates lack of
model adjustment.
We assessed the discriminatory capacity of the risk models,
as well as serum urea, for mortality by deriving their C-statis-
tics, using receiver operator characteristic (ROC) curves. In
general, a C-statistic value above 0.70 has acceptable discrim-
inatory capacity. The C-statistics were compared to each other
using a non-parametric test developed by DeLong et al. [8].
Survival for risk score categories for each scoring system
was compared with Kaplan-Meier curves and the log-rank
statistic.
To evaluate the ability of each scoring system to identify
patients at risk of early (1-year) mortality following ICD im-
plant, the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were calculated
for each scoring system and urea.
Cox proportional hazards regressionmodelling was used to
evaluate the relationship between each scoring system and the
occurrence of appropriate and inappropriate ICD therapy dur-
ing follow-up.
SPSS (version 21.0, SPSS Inc., Chicago, Illinois, USA)
was used for the statistical analysis. The areas under the
ROC curve for clinical event models were compared using
MedCalc (version 15.8, MedCalc Software, Mariakerke,




The study cohort was composed of 406 patients (Table 2). The
most common underlying aetiology was coronary artery dis-
ease (70.2%, n = 285) and the majority were primary preven-
tion implants (58.4%, n = 237).
3.2 Predictors of mortality
During a mean follow-up of 936 ± 560 days, 96 patients died.
In univariate Cox regression analyses, the absolute score of
each scoring system was significantly associated with surviv-
al, with higher scores associated with worse survival
(P < 0.0001 for all scoring systems) (Table 3). In addition,
apart from AF, all risk factors included in each scoring system
were also significantly associated with mortality (Table 3).
In multivariate analysis, including both the four risk scores as
well as their individual components, the only independent pre-
dictors of mortality were the Kramer scoring system (P = 0.032),
the Bilchick scoring system (P= 0.008), serum urea >9.28mmol/
L (P = 0.006) and peripheral arterial disease (P = 0.024).
3.3 Comparison of risk model discrimination
The calibration of the Goldenberg, Bilchick, Kramer and
Parkash scoring systems and urea for prediction of death were
Table 2 Baseline characteristics of the study population. Values are
median (interquartile range) or n (%)
Patient characteristics (n = 406)
Patient demographics




Diabetes mellitus 99 (24.6)
Coronary artery Disease 285 (70.2)
Peripheral vascular disease 98 (24.1)
Previous PCI 153 (37.3)
Previous CABG 112 (27.6)





QRS duration (ms) 130 (108–156)
Sinus 317 (78.1)
Atrial fibrillation/flutter 79 (19.4)
Heart block/paced 10 (2.5)
Pre-implantation blood results
Urea (mmol/L) 7 (5.5–9.4)
eGFR (mLmin) 65 (50–81)
Haemoglobin level (g/dL) 12.9 (11.6–14.1)





Type of device implanted
Dual chamber ICD 124 (30.5)
CRT-D 183 (45.1)
Subcutaneous ICD 4 (1.0)
Indication for device implantation
Primary prevention 237 (58.4)
CABG coronary artery bypass graft, ICD implantable cardioverter-defibrilla-
tor, LVEF left ventricular ejection fraction, CRT-D cardiac resynchronisation
therapy-defibrillator, PCI percutaneous coronary intervention
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excellent, as demonstrated by the results of the Hosmer-
Lemeshow test (Table 4).
By calculating the area under the ROC curve, we evaluated
the accuracy of each scoring system and urea to predict 1- and
3-year mortality (Table 4). The C-statistic values for the
Kramer score (AUC 0.76–0.77), the Bilchick score (AUC
0.70–0.76) and urea (AUC 0.71–0.70) were consistently
above 0.7, suggesting good discrimination. In contrast, the
values for the Parkash and Goldenberg models were consis-
tently below 0.7.
These findings were broadly consistent across the sub-
groups of primary and secondary prevention devices, as well
as single/dual chamber ICDs and CRT-Ds (Table 4). However,
the C-statistic values tended to be higher in the CRT-D sub-
groups compared to the single/dual chamber ICDs.
Additionally, while there was a trend towards the C-statistic
values being higher in the non-ischaemic cardiomyopathy
(NICM) subgroup compared to those with ischaemic cardio-
myopathy, the model calibration was generally better in those
with ischaemic cardiomyopathy.
We compared the discriminative capacity of the four scor-
ing system and urea to predict 1- and 3-year mortality. The C-
statistics for the Kramer and Bilchick scores were significantly
higher than either the Parkash or Goldenberg scores at both
time points (P < 0.05) (Table 5). However, neither had signif-
icantly better discriminative capacity than urea for the predic-
tion of 1- or 3-year mortality (Table 5).
3.4 Identifying patients at high risk of early mortality
Using the published cut-off values for each scoring system the
proportion of ICD recipients in the high-risk groups were 5.9,
34.7, 7.4 and 21.4% for the Bilchick, Goldenberg, Kramer and
Parkash scoring systems, respectively (Table 6). For urea (cut-
off of >9.28 mM), the proportion was 25.1%. 1-year mortality
in these five high-risk groups ranged from 11.7%
(Goldenberg) to 40% (Kramer).
For each of the four scoring system and urea, Kaplan-Meier
survival analyses demonstrated significantly worse survival in
Table 3 Univariate and
multivariate analyses for




Univariate analysis Multivariate analysis
Hazard
ratio




Bilchick scoring system 1.009 1.007–1.012 <0.0001 1.004 1.001–1.007 0.008
Age ≥75 years 2.041 1.365–3.052 0.001
NYHA class >II 1.879 1.259–2.805 0.002
Atrial fibrillation 0.980 0.644–1.490 0.924
COPD 2.130 1.320–3.436 0.002
Chronic kidney disease 3.867 2.534–5.900 <0.0001
LVEF ≤20% 1.746 1.118–2.727 0.014
Diabetes mellitus 2.703 1.804–4.050 <0.0001
Goldenberg scoring system 1.567 1.352–1.818 <0.0001
NYHA class >II 1.879 1.259–2.805 0.002
Age >70 years 2.101 1.374–3.212 0.001
Urea >9.28 mmol/L 5.033 3.282–7.721 <0.0001 2.123 1.238–3.643 0.006
QRS duration >120 ms 2.082 1.339–3.237 0.001
Atrial fibrillation 0.980 0.644–1.490 0.924
Kramer scoring system 2.249 1.880–2.691 <0.0001 1.351 1.026–1.779 0.032
Peripheral arterial disease 3.944 2.639–5.894 <0.0001 1.842 1.082–3.135 0.024
Age ≥70 years 2.017 1.315–3.095 0.001
Creatinine ≥177 μmol/L 2.434 1.853–3.198 <0.0001
LVEF ≤20% 1.746 1.118–2.727 0.014
Parkash scoring system 1.719 1.370–2.146 <0.0001
Age >80 years 1.763 1.029–3.021 0.039
Atrial fibrillation 0.980 0.644–1.490 0.924
Creatinine >159 μmol/L 4.963 3.067–8.031 <0.0001
NYHA class >II 1.879 1.259–2.805 0.002
CI confidence interval,COPD chronic obstructive pulmonary disease,NYHANewYork Heart Association, LVEF
left ventricular ejection fraction
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high- compared to low-risk patients (P < 0.0001 for each
analysis) (Fig. 1).
Overall, in our cohort, 1-year mortality was 8.1%
(n = 33). Of these 33 patients, 8 (24.2%) received doc-
umented appropriate ICD therapy (ATP or shocks) and
2 (6.1%) received inappropriate ICD therapy prior to
death. The scoring system that identified the largest
proportion of these 33 patients was urea (n = 19, sen-
sitivity 57.6%).
The sensitivity, specificity, PPV and NPV for each of the
scoring systems and urea to predict 1-year mortality are shown
in Table 6.
3.5 Relationship of scoring systems to device therapy
During follow-up, 106 (26.1%) patients experienced appropri-
ate device therapy (36 atp, 30 shock and 40 atp followed by
shock) and 38 (9.4%) patients inappropriate therapy (18 atp,
12 shock and 8 atp followed by shock). In univariate cox
regression analyses, only the Kramer scoring system was as-
sociated with the occurrence of appropriate device therapy
(hazard ratio 3.15, P = 0.003) (Table 7). None of the scoring
systems were associated with the occurrence of inappropriate
therapy.
4 Discussion
There are two main findings of this study. First, using
published scoring systems, a significant proportion of cur-
rent ICD recipients—between 6 and 35% in our cohort—
are at high risk of early mortality following device im-
plantation. Second, although all of the published scoring
systems we evaluated predicted post-implant mortality,
none significantly outperformed serum urea in terms of
discrimination.
ICD therapy significantly improves survival in the low-
LVEF patient population by the successful termination of
ventricular arrhythmias that underlie preventable SCD.
However, it has no impact on the risk of non-SCD. On
the basis of results from multiple large controlled
randomised (RCTs) trials, ICD therapy is targeted at pa-
tients at highest SCD risk. However, its clinical effective-
ness is critically dependent not only on the risk of SCD
but also on the risk of non-SCD [5, 9].
Table 6 Predictive accuracy of the Bilchick, Goldenberg, Kramer and Parkash scoring systems and urea for the prediction of 1-year mortality post-
ICD implantation in 406 new ICD implants






Sensitivity Specificity PPV NPV
% % % %
(95% CI) (95% CI) (95% CI) (95% CI)
Bilchick 24 7 (29.2) 21.2 95.4 29.2 93.2
(9.0–38.9) (92.8–97.3) (12.6–51.1) (90.2–95.5)
Goldenberg 141 16 (11.7) 48.5 66.5 11.4 93.6
(30.8–66.5) (61.5–71.3) (6.6–17.8) (89.9–66.2)
Kramer 30 12 (40.0) 36.4 9 5.2 40.0 94.4
(20.4–54.9) (92.5–97.1) (22.7–59.4) (91.6–96.5)
Parkash 87 11 (12.6) 33.3 79.6 12.6 93.1
(18.0–51.8) (75.2–83.6) (6.5–21.5) (89.7–95.6)
Urea 102 19 (18.6) 57.6 77.8 18.6 95.4
(39.2–74.5) (73.2–81.9) (11.6–27.6) (92.4–97.5)
CI confidence interval, NPV negative predictive value, PPV positive predictive value
Table 5 Comparison of C-statistics of the Bilchick, Goldenberg,
Kramer and Parkash scoring systems and urea for mortality at 1- and 3-
years
Comparison Death at 1 year Death at 3 years
z P value z P value
Urea vs. Goldenberg 2.688 <0.01 1.133 0.26
Urea vs. Bilchick 0.324 0.75 1.883 0.06
Urea vs. Kramer 1.302 0.19 1.421 0.16
Urea vs. Parkash 3.027 <0.01 1.769 0.08
Goldenberg vs. Bilhick 2.566 0.01 3.708 <0.001
Goldenberg vs. Kramer 3.678 <0.001 2.864 <0.01
Goldenberg vs. Parkash 1.170 0.24 1.464 0.14
Bilchick vs. Kramer 1.439 0.15 0.131 0.90
Bilchick vs. Parkash 3.369 <0.001 4.107 0.0001
Kramer vs. Parkash 4.040 0.0001 3.472 <0.001
The null-hypothesis z-test result is shown for the comparisons of the C-
statistic for the four scoring systems and urea, and respective P value,
obtained by the DeLong non-parametric method
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Using a simplified version of the Seattle Heart Failure
Model, the SCD-HeFT investigators created a risk prediction
model to divide the 2487 study patients into quintiles of increas-
ing predicted baseline mortality risk [9]. Although in the overall
study cohort ICD therapy improved survival, patients in the
highest risk quintile of predicted mortality did not benefit from
a device (relative risk for all-cause mortality 0.98, P = 0.89).
There were similar findings in an analysis of the 1232 patients
enrolled in MADIT-II, where again patients at highest pre-
implant mortality risk failed to gain benefit from their ICD
despite mortality benefit in the total study population [5].
Furthermore, it is possible that in some cases, ICD therapy
may actually increase the risk of non-SCD. The occurrence of
ICD shock therapy has been associated with worsening heart
failure status and an excess mortality [10]. In addition, unnec-
essary right ventricular pacing may also worsen LVEF and
increase mortality.
Although it is clear that some potential ICD recipients may
be too sick to gain meaningful benefit from ICD therapy, it is
unclear how best to accurately and reproducibly identify these
patients prior to device implantation. The current guidance is







































































High Risk (Urea > 9.28 mmol/L)  
Low Risk (Urea ≤ 9.28 mmol/L)  
Unadjusted P < 0.0001
High Risk (Score ≥ 3)  
Low Risk (Score 0 – 2)  
Unadjusted P < 0.0001
Unadjusted P < 0.0001
High Risk (Score ≥ 247)  
Low Risk (Score 246)  
Unadjusted P < 0.0001
High Risk (Score ≥ 3)  
Low Risk (Score 0 – 2)  
Fig. 1 a–d Kaplan-Meier
survival curves for survival
following ICD implantation in
different prognostic groups
according to the a Bilchick, b
Goldenberg, c Kramer scoring
systems and d urea
Table 7 Univariate and multivariate analyses for appropriate and
inappropriate ICD therapies by scoring system or urea level
Scoring system/clinical parameter Univariate analysis
Hazard ratio 95% CI P value
Appropriate ICD therapy (shocks or atp)
Bilchick scoring system 0.954 0.297–3.061 0.94
Goldenberg scoring system 1.230 0.702–2.154 0.47
Kramer scoring system 3.154 1.470–6.767 0.003
Parkash scoring system 1.513 0.830–2.761 0.18
Urea >9.28 mmol/L 1.141 0.590–2.204 0.70
Inappropriate ICD therapy (shocks or atp)
Bilchick scoring system 0.046 0–260.063 0.48
Goldenberg scoring system 1.780 0.723–4.383 0.21
Kramer scoring system 1.865 0.430–8.088 0.41
Parkash scoring system 1.744 0.662–4.589 0.26
Urea >9.28 mmol/L 1.226 0.440–3.412 0.70
CI confidence interval
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patients with advanced heart failure, defined as New York
Heart Association (NYHA) functional class IV, or in patients
who do not have a reasonable expectation of survival with an
acceptable functional status for at least a year [11]. However,
there is no provision of how best to risk stratify patients in
accordance with this guidance, making clinical interpretation
difficult. Moreover, NHYA class is a relatively inaccurate
prognostic variable, whose classification is often subjective.
A variety of alternative strategies to identify potential ICD
recipients with an elevated non-SCD risk have been proposed.
While early studies evaluated the use of individual risk
markers, such as renal function and age, recent investigators
have developed more complex risk scores in an attempt to
improve prediction [4–7]. These different approaches reflect
the observation that in the low-LVEF population, the main
contributor to non-SCD is pump failure, though non-cardiac
mortality may also play an important role in patients with
significant comorbidity.
Our finding that urea, a measure of renal function, is a
powerful marker of increased mortality following ICD im-
plantation is consistent with published data. In a meta-
analysis of patient-level data from 2867 patients enrolled in
three RCTs of prophylactic ICD therapy, Pun et al. found that
benefit from ICD therapy was strongly related to renal func-
tion, with impaired renal function at implant associated with a
decrease in survival benefit from a device [12]. These findings
have been reproduced by other investigators. These results
emphasize the uncertain benefit of ICD therapy in patients
with renal dysfunction and question the use of ICDs in this
patient population.
Our data suggest that despite consensus guidelines stating
that patients at increased short-term mortality risk should not
receive ICD therapy, many such patients are still implanted.
Using the four published scoring system in our cohort, 6 to
35% of implanted patients were identified to be at high risk of
short-term mortality.
In our cohort, while all four scoring systems predicted sur-
vival, the Kramer and Bilchick scores had the best discrimi-
native capacity, with C-statistics for both models consistently
0.7 or above for each of the two measured time points.
However, despite this, none of the scoring systems
outperformed serum urea, when evaluated using the area un-
der the ROC curves. Furthermore, pre-implant serum urea,
using the published cut-off of 9.28 mmol/L, identified the
largest proportion (58%) of patients who died within 1 year
of ICD implant.
When comparing predictive models, it is important to find
a balance between mathematical accuracy and clinical appli-
cability [13]. All of the proposed scoring systems used a min-
imum of four variables, with the Bilchick scoring system in-
cluding seven variables and a nomogram to calculate the over-
all risk. In contrast, serum urea is universally available and
simple to use.
Post hoc analysis of SCD-HeFT suggested a threshold of
benefit may be present based on an annual mortality risk of
20–25%, with patients at greater annualised risk than this un-
likely to benefit from an ICD [9]. Interestingly, 1-year mortal-
ity in the Kramer model (40%), Bilchick model (29%) and
urea (19%) were all around this level. This supports the pos-
sibility that these models not only identify patients at high risk
of mortality but also a group that may not benefit from ICD
therapy.
The issue of identifying patients who fulfill current inter-
national guidelines but are unlikely to gain significant survival
benefit from ICD therapy due to their high non-SCD risk is an
important one. ICDs continue to be an expensive technology,
and avoiding implanting patients who are unlikely to gain
survival benefit is likely to improve clinical and cost-effective-
ness. Furthermore, avoiding implanting unnecessary ICDs
would prevent exposing patients with advanced cardiac and
non-cardiac disease to the risks and potential complications of
a high-energy device.
5 Limitations
Our study has several potential limitations. First, it is a single-
centre retrospective analysis and at risk of the inherent bias of
this type of study. Although we analysed patients’ electronic
records in detail, it is possible that important clinical variables
used in the scoring systems, such as the presence or absence of
PAD, were not recorded adequately. This may have resulted in
a miscalculation of patients’ individual risk scores and impact-
ed on our results.
Second, although we included data on 406 patients with 96
deaths, our analysis is relatively small by the standards of
previous studies in this area.
Third, in our analysis, we included an unselected popula-
tion of primary and secondary prevention patients, patients
with CRT and non-CRT ICDs and patients with both ischae-
mic cardiomyopathy and NICM. The rationale for this was
that the issue of identifying patients too sick to benefit from
ICD therapy is important in all potential ICD recipients, irre-
spective of their ICD indication or the aetiology of their car-
diac disease. However, some of the prediction models we
evaluated were developed in purely primary prevention pop-
ulations, or patients with only single/dual chamber ICDs,
which may reduce their accuracy when evaluated in a mixed
population. In addition, the recent publication of the DANISH
study may impact on the guidelines for prophylactic ICD im-
plantation in the NICM population [14]. For this reason, we
have performed subgroup analyses based on indication, type
of device and aetiology of cardiac disease.
Furthermore, when making decisions regarding complex
device therapy for individual patients, it is important to bal-
ance the potential benefits against the risks. The benefit from
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ICD therapy is likely to be influenced by the indication (pri-
mary vs. secondary prevention), as well as the concomitant
use of CRT. Although the association between the risk factors/
models and mortality was relatively consistent across the dif-
ferent patient groups (primary/secondary prevention and ICD/
CRT-D recipients), the numbers in each group are relatively
small, and these models should be used with caution in pa-
tients with secondary prevention indications or CRT devices.
Fourth, given the observational design of our study, it is not
possible to establish cause of death, which may have influ-
enced interpretation of our results. However, all of the scoring
systems we evaluated were designed to predict all-cause mor-
tality and in none of the studies was cause or mode of death
given.
Lastly, it is an observational study, and therefore, it is not
possible to say that patients who died did not have their life
meaningfully prolonged by ICD therapy.
6 Conclusion
Using published scoring systems, a significant proportion of
current ICD recipients are at high risk of short-term mortality
following device implantation. Although all of the four pub-
lished scoring systems we evaluated predicted early mortality
following ICD implantation, none outperformed serum urea.
We advocate the use of urea as a simple, clinically applicable,
risk marker to better identify patients at high risk of early
mortality post-ICD implantation.
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